Retractable Technologies (RVP) AI Stock Analysis

• Market Cap: $21.70M
• Dividend Yield: N/A
• Average Volume (3M): 33.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.71
• Revenue Growth: -24.19%
• EPS Growth: -67.34%
• Country: US
• Employees: 221
• Sector: Healthcare
• Sector Strength: 70
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.40
• Shares Outstanding: 29,937,159
• 10 Day Avg. Volume: 43,848
• 30 Day Avg. Volume: 33,958
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -1.04
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 21.87
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Retractable Technologies is facing significant financial challenges with declining revenues and profitability, impacting its overall financial performance. While the technical analysis shows some recent upward momentum, valuation remains a concern due to negative earnings. The company's ability to stabilize cash flow and improve revenue generation will be crucial for future performance.

Retractable Technologies Business Overview & Revenue Model

Company Description

Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. It offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. The company distributes its products through general line and specialty distributors, as well as through international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.

How the Company Makes Money

Retractable Technologies generates revenue through the sale of its safety-engineered medical products, particularly its retractable safety syringes. The company sells these products to healthcare providers, hospitals, and clinics, as well as through distribution partnerships with medical supply companies. Revenue is driven by product sales, and any significant partnerships with large healthcare organizations or distributors can have a substantial impact on earnings. The adoption of safety regulations and standards in healthcare settings that prioritize needlestick prevention also serves as a critical factor contributing to the company's revenue growth.

Retractable Technologies Financial Statement Overview

Summary

Retractable Technologies faces significant challenges with declining revenues and profitability issues impacting the income statement. The balance sheet remains stable with manageable debt levels, but declining cash reserves and assets could become a concern. Cash flow stability is uncertain due to inconsistent free cash flow performance. The company needs to address revenue generation and cost management to improve financial health.

Income Statement

The income statement shows a significant decline in revenue over recent years, with 2024 experiencing no revenue. Gross profit has turned negative, and net income has been consistently negative for the past three years, indicating profitability issues. Margins have shrunk significantly, turning negative, which reflects operational challenges and increased costs relative to revenue.

Balance Sheet

The balance sheet reveals a relatively stable equity position, though there is a slight decline in stockholders' equity. The debt-to-equity ratio remains low, indicating manageable leverage levels. However, the decrease in total assets and cash reserves could pose a risk if financial performance does not improve.

Cash Flow

Cash flow analysis indicates stable operating cash flow despite declining revenues, but free cash flow has fluctuated significantly, turning negative at times. The cash flow to net income ratios are inconsistent, reflecting challenges in converting earnings into cash. Continued negative free cash flow could impact future liquidity.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	43.60M	94.82M	188.38M	81.86M
	Gross Profit
-1.03M	9.11M	28.25M	95.35M	37.01M
	EBIT
-21.11M	-11.49M	2.99M	72.60M	24.07M
	EBITDA
-21.11M	-1.24M	9.94M	76.44M	27.17M
	Net Income Common Stockholders
-11.89M	-7.01M	5.08M	56.06M	24.22M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.24M	47.29M	49.38M	42.43M	25.65M
	Total Assets
160.72M	179.67M	195.67M	206.30M	104.97M
	Total Debt
332.48K	1.54M	1.82M	2.10M	3.74M
	Net Debt
-3.90M	-11.13M	-17.90M	-27.06M	-13.83M
	Total Liabilities
73.55M	80.38M	89.13M	107.14M	55.09M
	Stockholders Equity
87.17M	99.29M	106.54M	99.17M	49.88M
Cash Flow		Free Cash Flow
1.91M	1.91M	-61.95K	-25.57M	-2.05M
	Operating Cash Flow
2.77M	2.77M	16.77M	32.79M	19.00M
	Investing Cash Flow
-10.76M	-10.76M	-31.20M	-63.04M	-19.33M
	Financing Cash Flow
941.64K	941.64K	4.99M	41.84M	11.96M

Retractable Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVP, the sentiment is Negative. The current price of 0.72 is above the 20-day moving average (MA) of 0.71, below the 50-day MA of 0.74, and below the 200-day MA of 0.80, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.70 is Neutral, neither overbought nor oversold. The STOCH value of 79.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RVP.

Retractable Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MHUA	57 Neutral	$7.43M	0.75	6.43%	―	-2.53%	34.36%
RVP	52 Neutral	$21.70M	―	-12.75%	―	-24.19%	-67.34%
Sector *	51 Neutral	$5.35B	3.41	-40.48%	2.89%	17.92%	2.25%
MLSS	50 Neutral	$71.54M	―	-68.09%	―	-12.19%	36.73%
FEMY	39 Underperform	$31.49M	―	-182.18%	―	51.97%	9.94%
AKYA	39 Underperform	$64.79M	―	-180.44%	―	-15.48%	24.53%